COVID-19:
WHY THE MOROCCAN PHARMA INDUSTRY MATTERS TO EUROPE
D
uring the past six months, the Moroccan pharmaceutical industry has shown a high degree of reliability and resilience. Put under extreme stress by a strong demand, especially for treatments included in the therapeutic protocol for Covid-19, the Kingdom’s local pharma manufacturers doubled their eorts to ensure na onal supply for essen al drugs.
24 europeanbusinessmagazine.com
Under the leadership of King Mohammed VI, The Moroccan Pharma Industry mobilized all of its production capacity from the outset to maintain its ac vity in the best condi ons and secure the supply of raw materials and finished products in order to avoid any possible shortage. Thanks to the agility and an cipa on of Moroccan manufacturers in this strategic sector which employs more
than 50,000 people, no stock shortage of locally manufactured drugs has been recorded, par cularly for molecules that are part of the treatment protocol against Covid-19, including Paracetamol, Vitamin C, Hydroxychloroquine, Azythromycin, Heparin, or Amoxi-clav. The production and distribu on of several million boxes have been ensured con nuously for the benefit of the Ministry of Health,
